Biomarkers
DNA remains a predominant biomarker wont to establish familial varieties of neurodegenerative diseases, numerous types of polymer have additional recently been joined to familial and noncontinuous forms of neurodegenerative diseases throughout the past few years. Imaging approaches still evolve and are creating major contributions to focus on engagement and early diagnostic biomarkers. Incorporation of biomarkers into drug development and clinical trials for neurodegenerative diseases guarantees to help within the development and demonstration of target engagement and drug effectiveness for medical specialty disorders.
- Anemia
- Novel therapeutics to treat cerebrovascular diseases
Related Conference of Biomarkers
June 22-23, 2026
18th Global Neurologists Meeting on Neurology and Neurosurgery
Amsterdam, Netherlands
June 29-30, 2026
31st International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences
Paris, France
July 20-21, 2026
11th International Conference on Central Nervous System Disorders & Therapeutics
Amsterdam, Netherlands
July 23-24, 2026
14th International Conference on Cannabis & Medicinal Research
Amsterdam, Netherlands
September 17-18, 2026
31st Global Experts Meeting on Neuroscience and Neuropharmacology
Paris, France
April 27-28, 2027
18th International Conference on Stroke, Neurology and Cerebrovascular Diseases
Paris, France